New insights into the pathogenesis of systemic sclerosis

Autoimmunity Reviews

Volumn 2, Issue 3, 2003, Pages 152-157

  Tamby, Mathieu C ^a   Chanseaud, Youri ^a   Guillevin, Loïc ^a,b   Mouthon, Luc ^a,b  

^a UFR SMBH Léonard de Vinci   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

Autoantibodies; Endothelial cells; Fibroblasts; Fibrosis; Microchimerism; Mononuclear cells; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; TRANSFORMING GROWTH FACTOR BETA; INTERLEUKIN 4;

COLLAGEN SYNTHESIS; CONNECTIVE TISSUE DISEASE; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; LYMPHOCYTE; MONOCYTE; MONONUCLEAR CELL; PATHOGENESIS; REVIEW; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; BIOLOGICAL MODEL; CD8+ T LYMPHOCYTE; CHIMERA; GENETICS; IMMUNOLOGY; METABOLISM; VASCULAR ENDOTHELIUM;

AUTOANTIBODIES; CD8-POSITIVE T-LYMPHOCYTES; CHIMERA; ENDOTHELIUM, VASCULAR; FIBROBLASTS; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0141819036     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(03)00004-1     Document Type: Review

References (40)

1. Clements P.J. Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Best Pract Res Clin Rheumatol. 14:2000;1-16.
2. Mouthon L., Garcia de la Pena-Lefebvre P., Chanseaud Y., Tamby M.C., Boissier M.C., Guillevin L. Pathogénie de la sclérodermie: aspects immunologiques. Ann Med Int. 153:2002;167-178.
3. Varga J., Bashey R.I. Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol. 12:1995;187-199.
4. Bogatkevich G.S., Tourkina E., Silver R.M., Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem. 276:2001;45184-45192.
5. Querfeld C., Eckes B., Huerkamp C., Krieg T., Sollberg S. Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci. 21:1999;13-22.
6. Leask A., Holmes A., Abraham D.J. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep. 4:2002;136-142.
7. Dong C., Zhu S., Wang T., et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA. 99:2002;3908-3913.
8. Leask A., Abraham D.J., Finlay D.R., et al. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum. 46:2002;1857-1865.
9. Leask A., Sa S., Holmes A., Shiwen X., Black C.M., Abraham D.J. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol. 54:2001;180-183.
10. Distler O., Pap T., Kowal-Bielecka O., et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 44:2001;2665-2678.
11. Fakhoury H., Hillarby M.C., Weiss J.B. Increased gelatinase activity in systemic sclerosis dermal fibroblast cultures with unaltered gelatinase A mRNA expression. J Dermatol Sci. 29:2002;62-69.
12. Akimoto S., Ishikawa O., Igarashi Y., Kurosawa M., Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol. 138:1998;399-406.
13. Gailit J., Marchese M.J., Kew R.R., Gruber B.L. The differentiation and function of myofibroblasts is regulated by mast cell mediators. J Invest Dermatol. 117:2001;1113-1119.
14. Yamamoto T., Katayama I., Nishioka K. Expression of stem cell factor in the lesional skin of systemic sclerosis. Dermatology. 197:1998;109-114.
15. Sakkas L.I., Xu B., Artlett C.M., Lu S., Jimenez S.A., Platsoucas C.D. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol. 168:2002;3649-3659.
16. Atamas S.P., Yurovski V.V., Wise R., et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum. 42:1999;1168-1178.
17. Majumdar S., Li D., Ansari T., et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J. 14:1999;251-257.
18. Chizzolini C., Rezzonico R., Ribbens C., Burger D., Wollheim F.A., Dayer J.M. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum. 41:1998;2039-2047.
19. Steen V.D., Powell D.L., Medsger T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 31:1988;196-203.
20. Diot E., Giraudeau B., Diot P., et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest. 116:1999;715-720.
21. Ferri C., Valentini G., Cozzi F., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 81:2002;139-153.
22. Okano Y., Steen V.D., Medsger T.A. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Int Med. 119:1993;1005-1013.
23. Okano Y., Steen V.D., Medsger T.A. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum. 35:1992;95-100.
24. Falkner D., Wilson J., Medsger T.A. Jr., Morel P.A. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum. 41:1998;74-80.
25. Oddis C.V., Okano Y., Rudert W.A., Trucco M., Duquesnoy R.J., Medsger T.A. Jr. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum. 35:1992;1211-1217.
26. Sugiura K., Muro Y. Anti-annexin V antibodies and digital ischemia in patients with scleroderma. J Rheumatol. 26:1999;2168-2172.
27. Riente L., Marchini B., Dolcher M.P., Puccetti A., Bombardieri S., Migliorini P. Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon. Clin Exp Immunol. 102:1995;354-359.
28. Akiyama Y., Tanaka M., Takeishi M., Adachi D., Mimori A., Suzuki T. Clinical, serological and genetic study in patients with CREST syndrome. Int Med. 39:2000;451-456.
29. Siracusa L.D., McGrath R., Ma Q., et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. PG, 300-13. Genome Res. 6:1996;300-313.
30. Murai C., Saito S., Kasturi K.N., Bona C.A. Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice. Autoimmunity. 28:1998;151-155.
31. Arnett F.C., Tan F.K., Uziel Y., et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum. 42:1999;2656-2659.
32. Negi V.S., Tripathy N.K., Misra R., Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 25:1998;462-466.
33. Carvalho D., Savage C.O., Black C.M., Pearson J.D. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest. 97:1996;111-119.
34. Sgonc R., Gruschwitz M., Boeck G., Sepp N., Gruber J., Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 43:2000;2550-2562.
35. Chizzolini C., Raschi E., Rezzonico R., et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum. 46:2002;1602-1613.
36. Artlett C.M., Smith J.B., Jimenez S.A. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med. 338:1998;1186-1191.
37. Nelson J.L., Furst D.E., Maloney S., et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet. 351:1998;559-562.
38. Arnett F.C., Cho M., Chatterjee S., Aguilar M.B., Reveille J.D., Mayes M.D. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 44:2001;1359-1362.
39. Tan F.K., Wang N., Kuwana M., et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum. 44:2001;893-901.
40. Fatini C., Gensini F., Sticchi E., et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med. 112:2002;540-544.